The centrosome: A target for cancer therapy

Current Cancer Drug Targets

Volumn 11, Issue 5, 2011, Pages 600-612

  Mazzorana, M ^a,b   Montoya, G ^a   Mortuza, G B ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b DIAMOND LIGHT SOURCE LTD   (United Kingdom)

Author keywords

Cancer; Cell cycle; Centrosome; Inhibitors; Kinases; Microtubule; Mitosis; Targets

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; ALISERTIB; ANTINEOPLASTIC AGENT; AT 7519; AURORA A KINASE; CENTRIN; CYCLIN DEPENDENT KINASE 1; DINACICLIB; ENMD 981693; FLAVOPIRIDOL; IROFULVEN; MK 1496; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; NCK PROTEIN; ON 01910; PF 477736; POLO LIKE KINASE 1; PROTEIN KINASE; SCAFFOLD PROTEIN; TERAMEPROCOL; TOZASERTIB; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; BINDING KINETICS; BLADDER TUMOR; BREAST CANCER; BREAST TUMOR; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE PROGRESSION; CENTROSOME; CHRONIC MYELOID LEUKEMIA; COILED BODY; COLON TUMOR; COLORECTAL CANCER; DRUG TARGETING; ESOPHAGEAL ADENOCARCINOMA; GENE OVEREXPRESSION; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; LUNG CANCER; LYMPHOMA; MACROMOLECULE; MELANOMA; MICROTUBULE; MICROTUBULE ORGANIZING CENTER; MITOSIS; MITOSIS SPINDLE; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR; TUMOR GROWTH;

EID: 79958151286     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911795655949     Document Type: Review

References (147)

1. Boveri, T. Zir Frange der entstenhung maligner Tumoren. Fischer Verlag 1914.
2. Bornens, M. Centrosome composition and microtubule anchoring mechanisms. Curr. Opin. Cell Biol. 2002, 14(1), 25-34.
3. Bettencourt-Dias, M.; Glover, D. M. Centrosome biogenesis and function: centrosomics brings new understanding. Nat. Rev. Mol. Cell Biol. 2007, 8(6), 451-463.
4. Glover, D. M.; Gonzalez, C.; Raff, J. W. The centrosome. Sci. Am. 1993, 268(6), 62-68.
5. Doxsey, S., Re-evaluating centrosome function. Nat. Rev. Mol. Cell Biol. 2001, 2(9), 688-698.
6. Jaensch, S.; Decker, M.; Hyman, A. A.; Myers, E. W. Automated tracking and analysis of centrosomes in early Caenorhabditis elegans embryos. Bioinformatics 26(12), i13-20.
7. Knockleby, J.; Lee, H. Same partners, different dance: involvement of DNA replication proteins in centrosome regulation. Cell Cycle 2010, 9(22), 4487-4491.
8. Nigg, E. A. Centrosome duplication: of rules and licenses. Trends Cell Biol. 2007, 17(5), 215-221.
9. Nigg, E. A. Centrosome aberrations: cause or consequence of cancer progression? Nat. Rev. Cancer 2002, 2(11), 815-825.
10. Knoblich, J. A. Asymmetric cell division: recent developments and their implications for tumour biology. Nat. Rev. Mol. Cell Biol. 2010, 11(12), 849-860.
11. Godinho, S. A.; Kwon, M.; Pellman, D. Centrosomes and cancer: how cancer cells divide with too many centrosomes. Cancer Metastasis Rev. 2009, 28(1-2), 85-98.
12. Marumoto, T.; Zhang, D.; Saya, H. Aurora-A-a guardian of poles. Nat. Rev. Cancer 2005, 5(1), 42-50.
13. Nogales-Cadenas, R.; Abascal, F.; Diez-Perez, J.; Carazo, J. M.; Pascual-Montano, A. CentrosomeDB: a human centrosomal proteins database. Nucleic Acids Res. 2009, 37(Database issue), D175-180.
14. Kramer, A.; Ho, A. D. Centrosome aberrations and cancer. Onkologie 2001, 24(6), 538-544.
15. Lingle, W. L.; Salisbury, J. L. The role of the centrosome in the development of malignant tumors. Curr. Top. Dev. Biol. 2000, 49, 313-329.
16. Salisbury, J. L.; Whitehead, C. M.; Lingle, W. L.; Barrett, S. L. Centrosomes and cancer. Biol. Cell 1999, 91(6), 451-460.
17. Hopkins, A. L.; Groom, C. R. The druggable genome. Nat. Rev. Drug Discov. 2002, 1(9), 727-730.
18. Sugiyama, Y. Druggability: selecting optimized drug candidates. Drug Discov. Today 2005, 10(23-24), 1577-1579.
19. Hinchcliffe, E. H.; Sluder, G. "It takes two to tango": understanding how centrosome duplication is regulated throughout the cell cycle. Genes Dev. 2001, 15(10), 1167-1181.
20. Fry, A. M.; Faragher, A. J. Identification of centrosome kinases. Methods Cell Biol. 2001, 67, 305-23.
21. Lacey, K. R.; Jackson, P. K.; Stearns, T. Cyclin-dependent kinase control of centrosome duplication. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(6), 2817-2822.
22. Johnson, L. N. Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev. Biophys. 2009, 42(1), 1-40.
23. Scapin, G. Protein kinase inhibition: different approaches to selective inhibitor design. Curr. Drug Targets 2006, 7(11), 1443-1454.
24. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351(Pt 1), 95-105.
25. Noble, M. E.; Endicott, J. A.; Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure. Science 2004, 303(5665), 1800-1805.
26. Chene, P. Drugs targeting protein-protein interactions. Chem. Med. Chem. 2006, 1(4), 400-411.
27. Janin, J. Wet and dry interfaces: the role of solvent in proteinprotein and protein-DNA recognition. Structure 1999, 7(12), R277-279.
28. DeLano, W. L. Unraveling hot spots in binding interfaces: progress and challenges. Curr. Opin. Struct. Biol. 2002, 12(1), 14-20.
29. Stockwin, L. H.; Holmes, S. Antibodies as therapeutic agents: vive la renaissance! Expert. Opin. Biol. Ther. 2003, 3(7), 1133-1152.
30. Arkin, M. R.; Wells, J. A. Small-molecule inhibitors of proteinprotein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 2004, 3(4), 301-317.
31. Horio, T.; Hotani, H. Visualization of the dynamic instability of individual microtubules by dark-field microscopy. Nature 1986, 321(6070), 605-607.
32. Mitchison, T.; Kirschner, M. Dynamic instability of microtubule growth. Nature 1984, 312(5991), 237-242.
33. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4(4), 253-265.
34. Andersen, J. S.; Wilkinson, C. J.; Mayor, T.; Mortensen, P.; Nigg, E. A.; Mann, M. Proteomic characterization of the human centrosome by protein correlation profiling. Nature 2003, 426(6966), 570-574.
35. Bahler, J.; Steever, A. B.; Wheatley, S.; Wang, Y.; Pringle, J. R.; Gould, K. L.; McCollum, D. Role of polo kinase and Mid1p in determining the site of cell division in fission yeast. J Cell Biol 1998, 143(6), 1603-1616.
36. Sumara, I.; Gimenez-Abian, J. F.; Gerlich, D.; Hirota, T.; Kraft, C.; de la Torre, C.; Ellenberg, J.; Peters, J. M., Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr. Biol. 2004, 14(19), 1712-1722.
37. Smits, V. A.; Klompmaker, R.; Arnaud, L.; Rijksen, G.; Nigg, E. A.; Medema, R. H. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat. Cell Biol. 2000, 2(9), 672-676.
38. Kotani, S.; Tugendreich, S.; Fujii, M.; Jorgensen, P. M.; Watanabe, N.; Hoog, C.; Hieter, P.; Todokoro, K. PKA and MPF-activated polo-like kinase regulate anaphase-promoting complex activity and mitosis progression. Mol. Cell 1998, 1(3), 371-380.
39. Golan, A.; Yudkovsky, Y.; Hershko, A. The cyclin-ubiquitin ligase activity of cyclosome/APC is jointly activated by protein kinases Cdk1-cyclin B and Plk. J. Biol. Chem. 2002, 277(18), 15552-15557.
40. Nogawa, M.; Yuasa, T.; Kimura, S.; Tanaka, M.; Kuroda, J.; Sato, K.; Yokota, A.; Segawa, H.; Toda, Y.; Kageyama, S.; Yoshiki, T.; Okada, Y.; Maekawa, T. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J. Clin. Invest. 2005, 115(4), 978-985.
41. Weichert, W.; Kristiansen, G.; Schmidt, M.; Gekeler, V.; Noske, A.; Niesporek, S.; Dietel, M.; Denkert, C. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J. Gastroenterol. 2005, 11(36), 5644-5650.
42. Weichert, W.; Ullrich, A.; Schmidt, M.; Gekeler, V.; Noske, A.; Niesporek, S.; Buckendahl, A. C.; Dietel, M.; Denkert, C. Expression patterns of polo-like kinase 1 in human gastric cancer. Cancer Sci. 2006, 97(4), 271-276.
43. Ahmad, N. Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer. FASEB J. 2004, 18(1), 5-7.
44. Kneisel, L.; Strebhardt, K.; Bernd, A.; Wolter, M.; Binder, A.; Kaufmann, R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002, 29(6), 354-358.
45. Yuan, J.; Horlin, A.; Hock, B.; Stutte, H. J.; Rubsamen-Waigmann, H.; Strebhardt, K. Polo-like kinase, a novel marker for cellular proliferation. Am. J. Pathol. 1997, 150(4), 1165-1172.
46. Strebhardt, K.; Ullrich, A. Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 2006, 6(4), 321-330.
47. Liu, Y.; Shreder, K. R.; Gai, W.; Corral, S.; Ferris, D. K.; Rosenblum, J. S. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem. Biol. 2005, 12(1), 99-107.
48. Gumireddy, K.; Reddy, M. V.; Cosenza, S. C.; Boominathan, R.; Baker, S. J.; Papathi, N.; Jiang, J.; Holland, J.; Reddy, E. P. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005, 7(3), 275-286.
49. Dai, W.; Liu, T.; Wang, Q.; Rao, C. V.; Reddy, B. S. Downregulation of PLK3 gene expression by types and amount of dietary fat in rat colon tumors. Int. J. Oncol. 2002, 20(1), 121-126.
50. Syed, N.; Smith, P.; Sullivan, A.; Spender, L. C.; Dyer, M.; Karran, L.; O'Nions, J.; Allday, M.; Hoffmann, I.; Crawford, D.; Griffin, B.; Farrell, P. J.; Crook, T. Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood 2006, 107(1), 250-256.
51. Li, B.; Ouyang, B.; Pan, H.; Reissmann, P. T.; Slamon, D. J.; Arceci, R.; Lu, L.; Dai, W. Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be downregulated in lung carcinomas. J. Biol. Chem. 1996, 271(32), 19402-19408.
52. Wiest, J.; Clark, A. M.; Dai, W. Intron/exon organization and polymorphisms of the PLK3/PRK gene in human lung carcinoma cell lines. Gene. Chromosomes Canc. 2001, 32(4), 384-389.
53. Fode, C.; Motro, B.; Yousefi, S.; Heffernan, M.; Dennis, J. W. Sak, a murine protein-serine/threonine kinase that is related to the Drosophila polo kinase and involved in cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(14), 6388-6392.
54. Hudson, J. W.; Kozarova, A.; Cheung, P.; Macmillan, J. C.; Swallow, C. J.; Cross, J. C.; Dennis, J. W. Late mitotic failure in mice lacking Sak, a polo-like kinase. Curr. Biol/ 2001, 11(6), 441-446.
55. Bettencourt-Dias, M.; Rodrigues-Martins, A.; Carpenter, L.; Riparbelli, M.; Lehmann, L.; Gatt, M. K.; Carmo, N.; Balloux, F.; Callaini, G.; Glover, D. M. SAK/PLK4 is required for centriole duplication and flagella development. Curr. Biol. 2005, 15(24), 2199-2207.
56. Habedanck, R.; Stierhof, Y. D.; Wilkinson, C. J.; Nigg, E. A. The Polo kinase Plk4 functions in centriole duplication. Nat. Cell Biol. 2005, 7(11), 1140-1146.
57. Ko, M. A.; Rosario, C. O.; Hudson, J. W.; Kulkarni, S.; Pollett, A.; Dennis, J. W.; Swallow, C. J. Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet 2005, 37(8), 883-888.
58. Li, J.; Tan, M.; Li, L.; Pamarthy, D.; Lawrence, T. S.; Sun, Y. SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing. Neoplasia 2005, 7(4), 312-323.
59. Cunha-Ferreira, I.; Rodrigues-Martins, A.; Bento, I.; Riparbelli, M.; Zhang, W.; Laue, E.; Callaini, G.; Glover, D. M.; Bettencourt-Dias, M. The SCF/Slimb ubiquitin ligase limits centrosome amplification through degradation of SAK/PLK4. Curr. Biol. 2009, 19(1), 43-49.
60. Rogers, G. C.; Rusan, N. M.; Roberts, D. M.; Peifer, M.; Rogers, S. L. The SCF Slimb ubiquitin ligase regulates Plk4/Sak levels to block centriole reduplication. J. Cell Biol. 2009, 184(2), 225-239.
61. Basto, R.; Brunk, K.; Vinadogrova, T.; Peel, N.; Franz, A.; Khodjakov, A.; Raff, J. W. Centrosome amplification can initiate tumorigenesis in flies. Cell 2008, 133(6), 1032-1042.
62. Castellanos, E.; Dominguez, P.; Gonzalez, C. Centrosome dysfunction in Drosophila neural stem cells causes tumors that are not due to genome instability. Curr. Biol. 2008, 18(16), 1209-1214.
63. Johnson, E. F.; Stewart, K. D.; Woods, K. W.; Giranda, V. L.; Luo, Y. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. Biochemistry 2007, 46(33), 9551-9563.
64. Xie, S.; Wu, H.; Wang, Q.; Cogswell, J. P.; Husain, I.; Conn, C.; Stambrook, P.; Jhanwar-Uniyal, M.; Dai, W. Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway. J. Biol. Chem. 2001, 276(46), 43305-43312.
65. Elia, A. E.; Rellos, P.; Haire, L. F.; Chao, J. W.; Ivins, F. J.; Hoepker, K.; Mohammad, D.; Cantley, L. C.; Smerdon, S. J.; Yaffe, M. B. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 2003, 115(1), 83-95.
66. Watanabe, N.; Sekine, T.; Takagi, M.; Iwasaki, J.; Imamoto, N.; Kawasaki, H.; Osada, H., Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J. Biol. Chem. 2009, 284(4), 2344-2353.
67. Reindl, W.; Yuan, J.; Kramer, A.; Strebhardt, K.; Berg, T. Inhibition of polo-like kinase 1 by blocking polo-box domaindependent protein-protein interactions. Chem. Biol. 2008, 15(5), 459-466.
68. Leung, G. C.; Hudson, J. W.; Kozarova, A.; Davidson, A.; Dennis, J. W.; Sicheri, F. The Sak polo-box comprises a structural domain sufficient for mitotic subcellular localization. Nat. Struct. Biol. 2002, 9(10), 719-724.
69. Cheng, K. Y.; Lowe, E. D.; Sinclair, J.; Nigg, E. A.; Johnson, L. N. The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex. EMBO J. 2003, 22(21), 5757-5768.
70. Kimura, M.; Matsuda, Y.; Yoshioka, T.; Okano, Y. Cell cycledependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3. J. Biol. Chem. 1999, 274(11), 7334-40.
71. Glover, D. M.; Leibowitz, M. H.; McLean, D. A.; Parry, H. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 1995, 81(1), 95-105.
72. Roghi, C.; Giet, R.; Uzbekov, R.; Morin, N.; Chartrain, I.; Le Guellec, R.; Couturier, A.; Doree, M.; Philippe, M.; Prigent, C. The Xenopus protein kinase pEg2 associates with the centrosome in a cell cycle-dependent manner, binds to the spindle microtubules and is involved in bipolar mitotic spindle assembly. J. Cell Sci. 1998, 111 (Pt 5), 557-572.
73. Tanaka, T.; Kimura, M.; Matsunaga, K.; Fukada, D.; Mori, H.; Okano, Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res. 1999, 59(9), 2041-2044.
74. Bischoff, J. R.; Anderson, L.; Zhu, Y.; Mossie, K.; Ng, L.; Souza, B.; Schryver, B.; Flanagan, P.; Clairvoyant, F.; Ginther, C.; Chan, C. S.; Novotny, M.; Slamon, D. J.; Plowman, G. D. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998, 17(11), 3052-3065.
75. Han, H.; Bearss, D. J.; Browne, L. W.; Calaluce, R.; Nagle, R. B.; Von Hoff, D. D. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 2002, 62(10), 2890-2896.
76. Sakakura, C.; Hagiwara, A.; Yasuoka, R.; Fujita, Y.; Nakanishi, M.; Masuda, K.; Shimomura, K.; Nakamura, Y.; Inazawa, J.; Abe, T.; Yamagishi, H. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br. J. Cancer 2001, 84(6), 824-831.
77. Zhou, H.; Kuang, J.; Zhong, L.; Kuo, W. L.; Gray, J. W.; Sahin, A.; Brinkley, B. R.; Sen, S. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet. 1998, 20(2), 189-193.
78. Ouchi, M.; Fujiuchi, N.; Sasai, K.; Katayama, H.; Minamishima, Y. A.; Ongusaha, P. P.; Deng, C.; Sen, S.; Lee, S. W.; Ouchi, T. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J. Biol. Chem. 2004, 279(19), 19643-13648.
79. Rojanala, S.; Han, H.; Munoz, R. M.; Browne, W.; Nagle, R.; Von Hoff, D. D.; Bearss, D. J. The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol. Cancer Ther. 2004, 3(4), 451-457.
80. Warner, S. L.; Gray, P. J.; Von Hoff, D. D. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others. Semin. Oncol. 2006, 33(4), 436-448.
81. Ditchfield, C.; Johnson, V. L.; Tighe, A.; Ellston, R.; Haworth, C.; Johnson, T.; Mortlock, A.; Keen, N.; Taylor, S. S. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 2003, 161(2), 267-280.
82. Yang, H.; Burke, T.; Dempsey, J.; Diaz, B.; Collins, E.; Toth, J.; Beckmann, R.; Ye, X. Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase. FEBS Lett. 2005, 579(16), 3385-3391.
83. Harrington, E. A.; Bebbington, D.; Moore, J.; Rasmussen, R. K.; Ajose-Adeogun, A. O.; Nakayama, T.; Graham, J. A.; Demur, C.; Hercend, T.; Diu-Hercend, A.; Su, M.; Golec, J. M.; Miller, K. M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 2004, 10(3), 262-267.
84. Tao, Y.; Zhang, P.; Frascogna, V.; Lecluse, Y.; Auperin, A.; Bourhis, J.; Deutsch, E. Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br. J. Cancer 2007, 97(12), 1664-1672.
85. Fiskus, W.; Wang, Y.; Joshi, R.; Rao, R.; Yang, Y.; Chen, J.; Kolhe, R.; Balusu, R.; Eaton, K.; Lee, P.; Ustun, C.; Jillella, A.; Buser, C. A.; Peiper, S.; Bhalla, K. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin. Cancer Res. 2008, 14(19), 6106-6115.
86. Bailly, E.; Doree, M.; Nurse, P.; Bornens, M. p34cdc2 is located in both nucleus and cytoplasm; part is centrosomally associated at G2/M and enters vesicles at anaphase. EMBO J. 1989, 8(13), 3985-3995.
87. Brown, N. R.; Lowe, E. D.; Petri, E.; Skamnaki, V.; Antrobus, R.; Johnson, L. N. Cyclin B and cyclin A confer different substrate recognition properties on CDK2. Cell Cycle 2007, 6(11), 1350-1359.
88. Kim, J. H.; Richter, J. D. RINGO/cdk1 and CPEB mediate poly(A) tail stabilization and translational regulation by ePAB. Genes Dev. 2007, 21(20), 2571-2579.
89. Malumbres, M.; Barbacid, M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 2005, 30(11), 630-641.
90. Santamaria, D.; Barriere, C.; Cerqueira, A.; Hunt, S.; Tardy, C.; Newton, K.; Caceres, J. F.; Dubus, P.; Malumbres, M.; Barbacid, M. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007, 448(7155), 811-815.
91. Yamamoto, H.; Monden, T.; Miyoshi, H.; Izawa, H.; Ikeda, K.; Tsujie, M.; Ohnishi, T.; Sekimoto, M.; Tomita, N.; Monden, M. Cdk2/cdc2 expression in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in colon cancer cells. Int. J. Oncol. 1998, 13(2), 233-239.
92. Kim, J. H.; Kang, M. J.; Park, C. U.; Kwak, H. J.; Hwang, Y.; Koh, G. Y. Amplified CDK2 and cdc2 activities in primary colorectal carcinoma. Cancer 1999, 85(3), 546-553.
93. Dobashi, Y.; Shoji, M.; Jiang, S. X.; Kobayashi, M.; Kawakubo, Y.; Kameya, T. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am. J. Pathol. 1998, 153(3), 963-972.
94. Cai, D.; Latham, V. M., Jr.; Zhang, X.; Shapiro, G. I. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res. 2006, 66(18), 9270-9280.
95. Fry, A. M.; Meraldi, P.; Nigg, E. A. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. EMBO J. 1998, 17(2), 470-481.
96. Quarmby, L. M.; Mahjoub, M. R. Caught Nek-ing: cilia and centrioles. J. Cell Sci. 2005, 118(Pt 22), 5161-5169.
97. Hayward, D. G.; Fry, A. M. Nek2 kinase in chromosome instability and cancer. Cancer Lett. 2006, 237(2), 155-166.
98. Fletcher, L.; Cerniglia, G. J.; Nigg, E. A.; Yend, T. J.; Muschel, R. J. Inhibition of centrosome separation after DNA damage: a role for Nek2. Radiat. Res. 2004, 162(2), 128-135.
99. Kokuryo, T.; Senga, T.; Yokoyama, Y.; Nagino, M.; Nimura, Y.; Hamaguchi, M. Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma. Cancer Res. 2007, 67(20), 9637-9642.
100. Salisbury, J. L. A mechanistic view on the evolutionary origin for centrin-based control of centriole duplication. J. Cell Physiol. 2007, 213(2), 420-428.
101. Salisbury, J. L.; Suino, K. M.; Busby, R.; Springett, M. Centrin-2 is required for centriole duplication in mammalian cells. Curr. Biol. 2002, 12(15), 1287-1292.
102. Rice, L. M.; Agard, D. A. Centriole duplication: centrin in on answers? Curr. Biol. 2002, 12(18), R618-619.
103. Lingle, W. L.; Barrett, S. L.; Negron, V. C.; D'Assoro, A. B.; Boeneman, K.; Liu, W.; Whitehead, C. M.; Reynolds, C.; Salisbury, J. L. Centrosome amplification drives chromosomal instability in breast tumor development. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(4), 1978-1983.
104. Lutz, W.; Lingle, W. L.; McCormick, D.; Greenwood, T. M.; Salisbury, J. L. Phosphorylation of centrin during the cell cycle and its role in centriole separation preceding centrosome duplication. J. Biol. Chem. 2001, 276(23), 20774-20780.
105. Gigant, B.; Wang, C.; Ravelli, R. B.; Roussi, F.; Steinmetz, M. O.; Curmi, P. A.; Sobel, A.; Knossow, M. Structural basis for the regulation of tubulin by vinblastine. Nature 2005, 435(7041), 519-522.
106. Checchi, P. M.; Nettles, J. H.; Zhou, J.; Snyder, J. P.; Joshi, H. C. Microtubule-interacting drugs for cancer treatment. Trends Pharmacol. Sci. 2003, 24(7), 361-365.
107. Vakifahmetoglu, H.; Olsson, M.; Zhivotovsky, B. Death through a tragedy: mitotic catastrophe. Cell Death Differ. 2008, 15(7), 1153-1162.
108. Kaur, G.; Hollingshead, M.; Holbeck, S.; Schauer-Vukasinovic, V.; Camalier, R. F.; Domling, A.; Agarwal, S., Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product. Biochem. J. 2006, 396(2), 235-242.
109. Sarli, V.; Giannis, A. Targeting the kinesin spindle protein: basic principles and clinical implications. Clin. Cancer Res. 2008, 14(23), 7583-7587.
110. Sawin, K. E.; LeGuellec, K.; Philippe, M.; Mitchison, T. J. Mitotic spindle organization by a plus-end-directed microtubule motor. Nature 1992, 359(6395), 540-543.
111. DeBonis, S.; Simorre, J. P.; Crevel, I.; Lebeau, L.; Skoufias, D. A.; Blangy, A.; Ebel, C.; Gans, P.; Cross, R.; Hackney, D. D.; Wade, R. H.; Kozielski, F. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5. Biochemistry 2003, 42(2), 338-349.
112. Mayer, T. U.; Kapoor, T. M.; Haggarty, S. J.; King, R. W.; Schreiber, S. L.; Mitchison, T. J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999, 286(5441), 971-974.
113. Whitehurst, A. W.; Bodemann, B. O.; Cardenas, J.; Ferguson, D.; Girard, L.; Peyton, M.; Minna, J. D.; Michnoff, C.; Hao, W.; Roth, M. G.; Xie, X. J.; White, M. A. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007, 446(7137), 815-819.
114. Smith, T. F.; Gaitatzes, C.; Saxena, K.; Neer, E. J. The WD repeat: a common architecture for diverse functions. Trends Biochem. Sci. 1999, 24(5), 181-185.
115. Li, D.; Roberts, R. WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cell Mol. Life Sci. 2001, 58(14), 2085-2097.
116. Luders, J.; Patel, U. K.; Stearns, T. GCP-WD is a gamma-tubulin targeting factor required for centrosomal and chromatin-mediated microtubule nucleation. Nat. Cell Biol. 2006, 8(2), 137-147.
117. Haren, L.; Remy, M. H.; Bazin, I.; Callebaut, I.; Wright, M.; Merdes, A. NEDD1-dependent recruitment of the gamma-tubulin ring complex to the centrosome is necessary for centriole duplication and spindle assembly. J. Cell Biol. 2006, 172(4), 505-515.
118. Tillement, V.; Haren, L.; Roullet, N.; Etievant, C.; Merdes, A. The centrosome protein NEDD1 as a potential pharmacological target to induce cell cycle arrest. Mol. Cancer 2009, 8, 10.
119. Marumoto, T.; Hirota, T.; Morisaki, T.; Kunitoku, N.; Zhang, D.; Ichikawa, Y.; Sasayama, T.; Kuninaka, S.; Mimori, T.; Tamaki, N.; Kimura, M.; Okano, Y.; Saya, H. Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells. Genes Cells 2002, 7(11), 1173-1182.
120. Giet, R.; McLean, D.; Descamps, S.; Lee, M. J.; Raff, J. W.; Prigent, C.; Glover, D. M. Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules. J. Cell Biol. 2002, 156(3), 437-451.
121. Kinoshita, K.; Habermann, B.; Hyman, A. A. XMAP215: a key component of the dynamic microtubule cytoskeleton. Trends Cell Biol. 2002, 12(6), 267-273.
122. Conte, N.; Delaval, B.; Ginestier, C.; Ferrand, A.; Isnardon, D.; Larroque, C.; Prigent, C.; Seraphin, B.; Jacquemier, J.; Birnbaum, D. TACC1-chTOG-Aurora A protein complex in breast cancer. Oncogene 2003, 22(50), 8102-8116.
123. Brittle, A. L.; Ohkura, H. Centrosome maturation: Aurora lights the way to the poles. Curr. Biol. 2005, 15(21), R880-882.
124. Jacquemier, J.; Ginestier, C.; Rougemont, J.; Bardou, V. J.; Charafe-Jauffret, E.; Geneix, J.; Adelaide, J.; Koki, A.; Houvenaeghel, G.; Hassoun, J.; Maraninchi, D.; Viens, P.; Birnbaum, D.; Bertucci, F. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res. 2005, 65(3), 767-779.
125. Mendiola, M.; Barriuso, J.; Marino-Enriquez, A.; Redondo, A.; Dominguez-Caceres, A.; Hernandez-Cortes, G.; Perez-Fernandez, E.; Sanchez-Navarro, I.; Vara, J. A.; Suarez, A.; Espinosa, E.; Gonzalez-Baron, M.; Palacios, J.; Hardisson, D. Aurora kinases as prognostic biomarkers in ovarian carcinoma. Hum. Pathol. 2009, 40(5), 631-638.
126. Cassimeris, L.; Morabito, J. TOGp, the human homolog of XMAP215/Dis1, is required for centrosome integrity, spindle pole organization, and bipolar spindle assembly. Mol. Biol. Cell 2004, 15(4), 1580-1590.
127. Slep, K. C.; Vale, R. D. Structural basis of microtubule plus end tracking by XMAP215, CLIP-170, and EB1. Mol. Cell 2007, 27(6), 976-991.
128. Popov, A. V.; Pozniakovsky, A.; Arnal, I.; Antony, C.; Ashford, A. J.; Kinoshita, K.; Tournebize, R.; Hyman, A. A.; Karsenti, E. XMAP215 regulates microtubule dynamics through two distinct domains. EMBO J. 2001, 20(3), 397-410.
129. Howard, J.; Hyman, A. A. Growth, fluctuation and switching at microtubule plus ends. Nat. Rev. Mol. Cell Biol. 2009, 10(8), 569-574.
130. Slep, K. C. The role of TOG domains in microtubule plus end dynamics. Biochem. Soc. Trans. 2009, 37(Pt 5), 1002-1006.
131. Al-Bassam, J.; Larsen, N. A.; Hyman, A. A.; Harrison, S. C. Crystal structure of a TOG domain: conserved features of XMAP215/Dis1-family TOG domains and implications for tubulin binding. Structure 2007, 15(3), 355-362.
132. De Luca, M.; Brunetto, L.; Asteriti, I. A.; Giubettini, M.; Lavia, P.; Guarguaglini, G. Aurora-A and ch-TOG act in a common pathway in control of spindle pole integrity. Oncogene 2008, 27(51), 6539-6549.
133. Peset, I.; Vernos, I. The TACC proteins: TACC-ling microtubule dynamics and centrosome function. Trends Cell Biol. 2008, 18(8), 379-388.
134. Lauffart, B.; Howell, S. J.; Tasch, J. E.; Cowell, J. K.; Still, I. H. Interaction of the transforming acidic coiled-coil 1 (TACC1) protein with ch-TOG and GAS41/NuBI1 suggests multiple TACC1-containing protein complexes in human cells. Biochem. J. 2002, 363(Pt 1), 195-200.
135. Still, I. H.; Hamilton, M.; Vince, P.; Wolfman, A.; Cowell, J. K. Cloning of TACC1, an embryonically expressed, potentially transforming coiled coil containing gene, from the 8p11 breast cancer amplicon. Oncogene 1999, 18(27), 4032-4038.
136. Raff, J. W. Centrosomes and cancer: lessons from a TACC. Trends Cell Biol. 2002, 12(5), 222-225.
137. Gergely, F. Centrosomal TACCtics. Bioessays 2002, 24(10), 915-925.
138. Lauffart, B.; Vaughan, M. M.; Eddy, R.; Chervinsky, D.; DiCioccio, R. A.; Black, J. D.; Still, I. H. Aberrations of TACC1 and TACC3 are associated with ovarian cancer. BMC Womens Health 2005, 5, 8.
139. Lee, M. J.; Gergely, F.; Jeffers, K.; Peak-Chew, S. Y.; Raff, J. W. Msps/XMAP215 interacts with the centrosomal protein D-TACC to regulate microtubule behaviour. Nat. Cell Biol. 2001, 3(7), 643-649.
140. Peset, I.; Seiler, J.; Sardon, T.; Bejarano, L. A.; Rybina, S.; Vernos, I. Function and regulation of Maskin, a TACC family protein, in microtubule growth during mitosis. J. Cell Biol. 2005, 170(7), 1057-1066.
141. O'Brien, L. L.; Albee, A. J.; Liu, L.; Tao, W.; Dobrzyn, P.; Lizarraga, S. B.; Wiese, C., The Xenopus TACC homologue, maskin, functions in mitotic spindle assembly. Mol. Biol. Cell 2005, 16(6), 2836-2847.
142. Pascreau, G.; Delcros, J. G.; Cremet, J. Y.; Prigent, C.; Arlot-Bonnemains, Y. Phosphorylation of maskin by Aurora-A participates in the control of sequential protein synthesis during Xenopus laevis oocyte maturation. J. Biol. Chem. 2005, 280(14), 13415-13423.
143. Kinoshita, K.; Noetzel, T. L.; Pelletier, L.; Mechtler, K.; Drechsel, D. N.; Schwager, A.; Lee, M.; Raff, J. W.; Hyman, A. A. Aurora A phosphorylation of TACC3/maskin is required for centrosomedependent microtubule assembly in mitosis. J. Cell Biol. 2005, 170(7), 1047-1055.
144. Maris, J. M.; Morton, C. L.; Gorlick, R.; Kolb, E. A.; Lock, R.; Carol, H.; Keir, S. T.; Reynolds, C. P.; Kang, M. H.; Wu, J.; Smith, M. A.; Houghton, P. J. Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer.
145. Manfredi, M. G.; Ecsedy, J. A.; Meetze, K. A.; Balani, S. K.; Burenkova, O.; Chen, W.; Galvin, K. M.; Hoar, K. M.; Huck, J. J.; LeRoy, P. J.; Ray, E. T.; Sells, T. B.; Stringer, B.; Stroud, S. G.; Vos, T. J.; Weatherhead, G. S.; Wysong, D. R.; Zhang, M.; Bolen, J. B.; Claiborne, C. F. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(10), 4106-4111.
146. Byrd, J. C.; Lin, T. S.; Dalton, J. T.; Wu, D.; Phelps, M. A.; Fischer, B.; Moran, M.; Blum, K. A.; Rovin, B.; Brooker-McEldowney, M.; Broering, S.; Schaaf, L. J.; Johnson, A. J.; Lucas, D. M.; Heerema, N. A.; Lozanski, G.; Young, D. C.; Suarez, J. R.; Colevas, A. D.; Grever, M. R. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007, 109(2), 399-404.
147. Steegmaier, M.; Hoffmann, M.; Baum, A.; Lenart, P.; Petronczki, M.; Krssak, M.; Gurtler, U.; Garin-Chesa, P.; Lieb, S.; Quant, J.; Grauert, M.; Adolf, G. R.; Kraut, N.; Peters, J. M.; Rettig, W. J. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr. Biol. 2007, 17(4), 316-322.